INM

InMed Pharmaceuticals Inc. (INM) | Rumor.io

InMed Pharmaceuticals

INM

Attention (50-day avg)0%

Attention rank (50-day avg)#3,318

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.01

Market capitalization7.5M

Earnings per share-2.8

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-12.6M

Social

What share of all stock conversation is about INM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 22

InMed Pharmaceuticals Inc. (INM) has announced a $200 million private placement with Mentari Therapeutics for its migraine prevention pipeline.
INM is experiencing a significant run, with some users predicting a potential gain of 100% and others holding onto the stock in hopes of reaching a target price of $10.
High short interest in INM may lead to a squeeze, and the company's small float after the merger is a notable factor in the market's attention to the stock.

Generated by AI

Sentiment

Of the messages about INM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.55% +5.71
Bearish	—	—	—	5.45% -5.71

Bullish· Jul 22

The company's private placement of $200 million is seen as a catalyst for a significant price increase, with some predicting a squeeze to $5.52 and a subsequent explosive run-up.
The company has a very small float, making it prone to significant price movements, and is considered a good play for those looking to capitalize on a potential rebound.
The stock has shown a strong bounce back and is carving out a double bottom, with some analysts predicting a potential run-up to $4-$5+ with the right catalysts.

Bearish· Jul 22

InMed Pharmaceuticals Inc. ($INM) has seen a significant drop in price, with some users expecting it to settle around $1.50.
The company's high short interest and dilution of shares are seen as contributing factors to its downward trend.
Some users are anticipating further price drops, citing the potential for increased shares outstanding and a decrease in cash reserves.

Generated by AI

Topics

Of the messages about INM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	74.25%
Technical Analysis	—	—	—	24.8%
Analysts	—	—	—	0.16%
Controversies	—	—	—	0%
Earnings	—	—	—	0.47%
Macro	—	—	—	0.31%

Analysts· Sep 12

InMed Pharmaceuticals (INM) shares have increased by 60% following a $6 million private placement.
The stock price has risen to $13.01, up 18% from the previous day's close, on above-average volume.
Analysts are likely monitoring the company's recent developments, including the private placement, to inform their INM stock price predictions and targets.

Announcements· May 19

InMed Pharmaceuticals (INM) is merging with private migraine biotech Mentari Therapeutics in an all-stock deal, creating a company focused on migraine prevention.
The combined company will operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol, with a market value of $421.4M and InMed shareholders owning a 1.51% stake.
The merger is backed by a $290M private placement led by top-tier investors, providing substantial capital to fund operations through 2028 and beyond.

Technical Analysis· May 19

$INM is considered toppy, but a break above $2 could lead to further gains.
The stock needs to break through key resistance levels, including the descending wedge and VWAP at $1.83, to continue its upward momentum.
A successful breakout above the pennant and VWAP at $1.86 could lead to significant gains, potentially reaching $2.50.

Generated by AI

Community

Of the messages about INM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	16.97%
Newcomers	—	—	100%	83.03%

Regulars· Jul 22

$INM is expected to have a huge run up if it reaches $5.52 due to a potential squeeze, with a lower float that can cause the price to explode quickly.
The $200 million private placement by Mentari Therapeutics is seen as a catalyst for $INM, with some participants targeting a price of $5.52 for the squeeze.
Some participants are cautious about shorting $INM, citing the potential for a reversal and the fact that shorts lose money all the time.

Newcomers· Jul 22

The focus of newcomers is on the high short interest in $INM, which could lead to a squeeze.
New investors are excited about the potential for a price increase after the merger, with some mentioning a small float as a reason for optimism.
Many newcomers are discussing the stock's price movements, with some expressing hope for a rebound after a recent decline.

Generated by AI

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the...

11d agoYahoo! Finance Canada

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026.The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com,...

20d agoYahoo Finance

Mentari merger financing reshapes InMed Pharmaceuticals’ future

Detailed price information for Inmed Pharmaceuticals Inc (INM-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.

2mo agoBenzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - InMed Pharmaceuticals (NASDAQ:INM), Chin

Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday's pre-market session. The company's market cap stands at $8.2 million. China SXT Pharmaceuticals (NASDAQ:SXTC)

2mo agoBenzinga

Also Discussed

Investors talking about INM also mention

#	Name	Attention
1	Shuttle Pharmaceuticals Holdings, Inc.SHPH	0%0
2	Kiora Pharmaceuticals Inc.KPRX	0%0
3	MGAM - Mobile Global Esports Inc.	——
4	PBLA - Panbela Therapeutics, Inc.	——
5	LIPO - Lipella Pharmaceuticals Inc.	——
6	Naya Biosciences Inc.INVO	0%0
7	SaverOne 2014 Ltd. ADRSVRE	0%new
8	Versus Systems Inc.VS	0%0
9	BioAffinity Technologies Inc.BIAF	0%+0
10	Tandy Leather Factory, Inc.TLF	0%0

InMed Pharmaceuticals Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based small molecule therapies and pharmaceutical-grade cannabinoid manufacturing technologies. The company’s current work centers on research and development programs targeting Alzheimer’s disease, ocular disorders, and dermatological conditions, including epidermolysis bullosa and glaucoma. InMed Pharmaceuticals also operates a commercial segment through BayMedica, which develops proprietary methods to produce and commercialize rare cannabinoids for use in health and wellness products and other ingredient markets. Its pipeline includes specialized product candidates and manufacturing platforms designed to support both therapeutic development and cannabinoid supply. Headquartered in Vancouver, Canada, InMed Pharmaceuticals plays a niche role in the biotechnology sector by combining drug discovery with cannabinoid-focused production capabilities.

Website

Location

885 West Georgia Street

Vancouver, BC, V6C 3E8

Canada

Social

What share of all stock conversation is about INM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 22

InMed Pharmaceuticals Inc. (INM) has announced a $200 million private placement with Mentari Therapeutics for its migraine prevention pipeline.
INM is experiencing a significant run, with some users predicting a potential gain of 100% and others holding onto the stock in hopes of reaching a target price of $10.
High short interest in INM may lead to a squeeze, and the company's small float after the merger is a notable factor in the market's attention to the stock.

Generated by AI

Sentiment

Of the messages about INM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.55% +5.71
Bearish	—	—	—	5.45% -5.71

Bullish· Jul 22

The company's private placement of $200 million is seen as a catalyst for a significant price increase, with some predicting a squeeze to $5.52 and a subsequent explosive run-up.
The company has a very small float, making it prone to significant price movements, and is considered a good play for those looking to capitalize on a potential rebound.
The stock has shown a strong bounce back and is carving out a double bottom, with some analysts predicting a potential run-up to $4-$5+ with the right catalysts.

Bearish· Jul 22

InMed Pharmaceuticals Inc. ($INM) has seen a significant drop in price, with some users expecting it to settle around $1.50.
The company's high short interest and dilution of shares are seen as contributing factors to its downward trend.
Some users are anticipating further price drops, citing the potential for increased shares outstanding and a decrease in cash reserves.

Generated by AI

Topics

Of the messages about INM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	74.25%
Technical Analysis	—	—	—	24.8%
Analysts	—	—	—	0.16%
Controversies	—	—	—	0%
Earnings	—	—	—	0.47%
Macro	—	—	—	0.31%

Analysts· Sep 12

InMed Pharmaceuticals (INM) shares have increased by 60% following a $6 million private placement.
The stock price has risen to $13.01, up 18% from the previous day's close, on above-average volume.
Analysts are likely monitoring the company's recent developments, including the private placement, to inform their INM stock price predictions and targets.

Announcements· May 19

InMed Pharmaceuticals (INM) is merging with private migraine biotech Mentari Therapeutics in an all-stock deal, creating a company focused on migraine prevention.
The combined company will operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol, with a market value of $421.4M and InMed shareholders owning a 1.51% stake.
The merger is backed by a $290M private placement led by top-tier investors, providing substantial capital to fund operations through 2028 and beyond.

Technical Analysis· May 19

$INM is considered toppy, but a break above $2 could lead to further gains.
The stock needs to break through key resistance levels, including the descending wedge and VWAP at $1.83, to continue its upward momentum.
A successful breakout above the pennant and VWAP at $1.86 could lead to significant gains, potentially reaching $2.50.

Generated by AI

Community

Of the messages about INM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	16.97%
Newcomers	—	—	100%	83.03%

Regulars· Jul 22

$INM is expected to have a huge run up if it reaches $5.52 due to a potential squeeze, with a lower float that can cause the price to explode quickly.
The $200 million private placement by Mentari Therapeutics is seen as a catalyst for $INM, with some participants targeting a price of $5.52 for the squeeze.
Some participants are cautious about shorting $INM, citing the potential for a reversal and the fact that shorts lose money all the time.

Newcomers· Jul 22

The focus of newcomers is on the high short interest in $INM, which could lead to a squeeze.
New investors are excited about the potential for a price increase after the merger, with some mentioning a small float as a reason for optimism.
Many newcomers are discussing the stock's price movements, with some expressing hope for a rebound after a recent decline.

Generated by AI

InMed Pharmaceuticals

Social

Jul 22

Bullish· Jul 22

Bearish· Jul 22

Analysts· Sep 12

Announcements· May 19

Technical Analysis· May 19

Regulars· Jul 22

Newcomers· Jul 22

InMed receives Nasdaq deficiency notice on equity requirement

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Mentari merger financing reshapes InMed Pharmaceuticals’ future

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - InMed Pharmaceuticals (NASDAQ:INM), Chin

Also Discussed

InMed Pharmaceuticals Inc.

Company Information

Location

InMed receives Nasdaq deficiency notice on equity requirement

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Mentari merger financing reshapes InMed Pharmaceuticals’ future

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - InMed Pharmaceuticals (NASDAQ:INM), Chin

Also Discussed

Social

Jul 22

Bullish· Jul 22

Bearish· Jul 22

Analysts· Sep 12

Announcements· May 19

Technical Analysis· May 19

Regulars· Jul 22

Newcomers· Jul 22